Oral Sun Protection in Melasma, Acne, and PIH: Clinical Needs and Considerations- Dr Ravindra Babu P

Pigmentary disorders represent a significant dermatological burden in India. Acne affects 66.6% of the population, while melasma (50.2%) and post-inflammatory hyperpigmentation (49.8%) are among the most frequently encountered hyperpigmentation presentations, with sun exposure identified as the primary etiological driver in more than half of the cases. Across all three conditions, sustained UV exposure on Fitzpatrick III–VI phototypes perpetuates disease activity and relapse. Topical sunscreens are the cornerstone of photoprotective management, yet adherence gaps and spectral limitations create a clinical void that have the potential to be addressed with oral photoprotection (1,2).

Why Topical Sun Protection is Often Not Sufficient in Real-World Practice? 

Standard topical sunscreens are insufficient in melasma as they do not block visible light, which independently drives melanogenesis. A double-blind RCT (n=68) found iron oxide sunscreen plus hydroquinone achieved 77.8% MASI improvement versus 61.9% with UV-only SPF 50. Similarly, in PIH, SPF blocks UV without suppressing inflammation; in 89 patients, SPF 60 outperformed SPF 30 in lightening hyperpigmentation over 8 weeks, yet PIH still develops 7–14 days post-laser despite SPF 50+ (3,4,5).

How do Oral Photoprotection Agents Work?

Ultraviolet UVA and UVB radiation generate reactive oxygen species (ROS) that drive oxidative stress, inflammation, and collagen breakdown in skin cells. Oral supplementation with a combination of clinically proven ingredients, including Mediterranean rosemary (Rosmarinus officinalis) and grapefruit (Citrus paradisi) extracts, provides systemic photoprotection by scavenging free radicals across both aqueous and lipid cellular compartments. In UV-irradiated keratinocytes, this blend significantly reduces intracellular ROS and proinflammatory cytokines (IL-1, IL-6, IL-8), while preserving procollagen and elastin secretion in fibroblasts (6,7).

Clinical Evidence for Oral Photoprotection: International and Recent Indian Evidence

Evidence for oral photoprotection is evolving from mechanistic promise to real-world applicability across group of pigmentary disorders, including melasma, acne and post-inflammatory hyperpigmentation.

Study 1-Multimodal Protective effects of Rosemary & Citrus Extracts-European Study: In a human volunteer study, 250 mg of the rosemary-grapefruit combination taken daily increased the Minimal Erythema Dose(MED) by 34% at 8 weeks and 56% at 12 weeks. In vitro, the blend reduced intracellular ROS, prevented DNA damage and inhibited tyrosinase activity. These research findings establish the core pharmacodynamic principle that systemic polyphenols can augment the skin's endogenous photoprotective capacity. (6)

Study 2-Golite-OSP Against Light-Induced Damage in Indian Population-Go-Real Study: A retrospective analysis of 850 adult patients (mean age 32.2 years; 59.2% female) showed acne as the leading indication (51.1%), followed by rosacea (30.8%) and eczema (10.9%). Once-daily dosing of the rosemary–grapefruit extract combination (Golite-OSP) 100 mg/day over a mean duration of 9.6 weeks yielded over 93% favourable efficacy and tolerability ratings by both physicians and patients. Adverse events were minimal (0.4%). Over 75% of patients reported positive skin benefits, with 58.7% noting improved skin lightness. This is the largest real-world dataset for any rosemary–grapefruit oral photoprotective agent, extending evidence into acne-associated photodamage and PIH prevention (8).

Study 3-Golite-OSP Benefit in Outdoor Active Professionals from South India- Case series: In 11 patients with Fitzpatrick IV–VI skin and hyperpigmentation of varying grades persisting ≥3 months, oral photoprotection with Rosmarinus Officinalis and Citrus Paradisi (Golite-OSP) 100 mg/day for 1 month yielded Skin Hyperpigmentation Index (SHI) improvement of at least one grade in all patients: maximum pigmentation (SHI-4) dropped to medium (SHI 2–3); severe (SHI 3–4) fell to light (SHI 1–2); medium (SHI 2–3) improved to light across all cases. No adverse events occurred. This study provides the first clinical evidence of oral photoprotection in Indian Fitzpatrick IV–VI phototypes, in high UV areas like South India, offering efficacy in reducing pigmentation with a favourable safety profile (9).

Applying Oral Photoprotection Agents Effectively in Practice

Melasma: Melasma relapses through windows, screens, and indirect light, where topical sun protection with SPF 50 serves suboptimal. Oral photoprotection aims to bridge this gap as an adjunct to topicals, lasers, and maintenance regimens. In the South Indian case series, all 11 patients improved by at least one SHI grade at one month, a directional signal supporting adjunctive use where topical SPF alone fails to prevent relapse. The absence of a control arm limits causal attribution, but the clinical rationale is well-supported by mechanistic and real-world data. (8)

Acne and Post-Acne PIH Attenuation: In Fitzpatrick IV–VI skin, UV exposure converts a resolving acne lesion into a months-long hyperpigmented mark. Systemic antioxidant and anti-inflammatory support may attenuate PIH severity, functioning as post-acne PIH prevention within the acne management plan. In the Go-Real cohort, acne was the leading indication; physician and patient efficacy ratings were consistently favourable, with the majority reporting improved skin lightness and uniform tone. (9)

Bridge between IV Glutathione Therapy Sessions: Intravenous (IV) glutathione, a very common component of routinely conducted anti-aging interventions, carries a short plasma half-life (~1.5–2 hours),with rapid clearance limiting sustained antioxidant coverage between sessions. Oral photoprotection serves as a practical bridge, maintaining systemic antioxidant activity during inter-treatment intervals. The rosemary–grapefruit polyphenol blend provides continuous ROS scavenging and tyrosinase inhibition, a once-daily dosing regimen, complementing the acute antioxidant surge achieved from IV glutathione. The mechanistic rationale for sequential use- acute parenteral replenishment followed by sustained oral maintenance, is clinically coherent for skin-lightening protocols (9,10).

                                                                                                  Figure 1: Oral Photoprotection – Clinical Considerations

Safety Considerations & Patient Counselling

Oral photoprotection agents can be considered in melasma, post-procedure PIH-prone patients, acne with active dark marks, and topical sunscreen reapplication non-compliers. Counsel the patient that oral photoprotection is strictly adjunctive, topical SPF remains non-negotiable. Visible pigment attenuation requires 8–12 weeks of consistent use, consistent with human volunteer data showing a 56% MED increase at 12 weeks. Once-daily dosing integrates easily with existing routines. Adverse events were rare (0.4%, mild GI only); 99.6% tolerated without issue. No photosensitivity risk, no dietary restrictions, and minimal drug interactions are documented. Reassess at 3 months if no benefit is perceived. (6,8)

Key Takeaways

● Oral photoprotection interventions are mechanistically complementary with rosemary-grapefruit polyphenols, providing systemic ROS scavenging and tyrosinase inhibition; covering the spectral and adherence gaps that topical sun protection cannot reliably address, more so among Indian Fitzpatrick III–VI phototypes.

● Evidence supports adjunctive use across all three major indications - melasma, acne-associated PIH, and as a sustained antioxidant bridge between IV glutathione sessions.

● More recently, Rosmarinus Officinalis and Citrus Paradisi (Golite-OSP) have been clinically proven as an oral photoprotection agent among Indian patients prone to the effects of light-induced damage. (8,9)

Abbreviations: ROS — reactive oxygen species; UV — ultraviolet; UVA — ultraviolet A; UVB — ultraviolet B; SPF — sun protection factor; PIH — post-inflammatory hyperpigmentation; MED — minimal erythema dose; SHI — Skin Hyperpigmentation Index; MASI — Melasma Area and Severity Index; RCT — randomised controlled trial; IL — interleukin; GI — gastrointestinal; IV — intravenous.